Research
Periodic Report
Alembic Pharma Gains on USFDA Nod, IRB Infra Rises on ₹9,270 Cr NHAI Project, Groww Parent Hits Upper Circuit
Alembic Pharma Gains on USFDA Nod, IRB Infra Rises on ₹9,270 Cr NHAI Project, Groww Parent Hits Upper Circuit
Written by - Fisdom Research
Array
November 17, 2025
2 minutes
Array
Market Snapshot
Indian equities extended gains for the second straight session on November 11, with the Nifty closing near 25,700 amid optimism over progress on the US government funding bill and prospects of a US–India trade deal.
The market opened firm tracking positive global cues but slipped into the red during the first half as investors turned cautious following recent geopolitical tensions.
Renewed buying in auto, metal, and IT stocks during the afternoon trade helped indices recover losses and finish the day near their highs.
Overall, sentiment remained buoyed by improving global risk appetite despite early volatility in the session.
Sectoral Trends
Sector Name
% Change
Sector Name
% Change
NIFTY PSU BANK
1.1
NIFTY CHEMICALS
0.6
NIFTY AUTO
0.9
NIFTY500 HEALTHCARE
0.6
NIFTY CONSUMER DURABLES
0.8
NIFTY REALTY
0.5
NIFTY PRIVATE BANK
0.8
NIFTY HEALTHCARE INDEX
0.4
Top News
Alembic Pharmaceuticals’ share rose 2% after receiving final USFDA approval for its Diltiazem Hydrochloride Tablets, therapeutically equivalent to Bausch Health’s Cardizem.
IRB Infrastructure’s stock gained over 5% after its private InvIT received a ₹9,270 crore project award from NHAI for the TOT-17 highway bundle.
Billionbrains Garage Ventures, Groww’s parent company, surged 20% to a new high as it continued its post-listing rally, reaching a market cap of ₹1.1 lakh crore.
Top Gainers and Losers
Top Gainers
% Change
Top Losers
% Change
ETERNAL
1.9
TMPV
-4.7
TATACONSUM
1.8
ULTRACEMCO
-0.8
MAXHEALTH
1.7
JIOFIN
-0.8
Share the article
Array
Get exclusive content
and expert advice
Subscribe to fisdom to get regular updates in the finance world delivered to your inbox each month
